Arbutus Biopharma
ABUS
ABUS
53 hedge funds and large institutions have $118M invested in Arbutus Biopharma in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 21 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
53
Holders Change
-2
Holders Change %
-3.64%
% of All Funds
1.32%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
13
Reduced
21
Closed
10
Calls
$106K
Puts
$175K
Net Calls
-$69K
Net Calls Change
+$498K
Top Buyers
| 1 |
RI
RTW Investments
New York
|
+$4.7M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$838K |
| 3 |
Renaissance Technologies
New York
|
+$359K |
| 4 |
Invesco
Atlanta,
Georgia
|
+$321K |
| 5 |
TI
Telemetry Investments
New York
|
+$244K |
Top Sellers
| 1 |
AWG
Alpha Wave Global
New York
|
-$1.75M |
| 2 |
AC
Armistice Capital
New York
|
-$1.11M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$573K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$469K |
| 5 |
Goldman Sachs
New York
|
-$398K |
